These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35361140)

  • 1. A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students.
    Lee CC; Segaloff HE; Cole D; Rosenblum HG; Morgan CN; Somers T; Desamu-Thorpe R; Foster MA; Currie D; Ruff J; Payne D; Whyte TJ; Abedi GR; Bigouette JP; Kahrs J; Langolf K; Remington P; Sterkel A; Kelly P; Westergaard RP; Bateman AC; Hsu CH; Tate JE; Kirking HL
    BMC Infect Dis; 2022 Mar; 22(1):314. PubMed ID: 35361140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and analytical evaluation of the Abbott AdviseDx quantitative SARS-CoV-2 IgG assay and comparison with two other serological tests.
    Maine GN; Krishnan SM; Walewski K; Trueman J; Sykes E; Sun Q
    J Immunol Methods; 2022 Apr; 503():113243. PubMed ID: 35181288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Seroconversion in Children and Adults With Mild COVID-19.
    Toh ZQ; Anderson J; Mazarakis N; Neeland M; Higgins RA; Rautenbacher K; Dohle K; Nguyen J; Overmars I; Donato C; Sarkar S; Clifford V; Daley A; Nicholson S; Mordant FL; Subbarao K; Burgner DP; Curtis N; Bines JE; McNab S; Steer AC; Mulholland K; Tosif S; Crawford NW; Pellicci DG; Do LAH; Licciardi PV
    JAMA Netw Open; 2022 Mar; 5(3):e221313. PubMed ID: 35262717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity.
    Bradley BT; Bryan A; Fink SL; Goecker EA; Roychoudhury P; Huang ML; Zhu H; Chaudhary A; Madarampalli B; Lu JYC; Strand K; Whimbey E; Bryson-Cahn C; Schippers A; Mani NS; Pepper G; Jerome KR; Morishima C; Coombs RW; Wener M; Cohen S; Greninger AL
    J Clin Microbiol; 2021 Aug; 59(9):e0098921. PubMed ID: 34165323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
    Letizia AG; Ge Y; Vangeti S; Goforth C; Weir DL; Kuzmina NA; Balinsky CA; Chen HW; Ewing D; Soares-Schanoski A; George MC; Graham WD; Jones F; Bharaj P; Lizewski RA; Lizewski SE; Marayag J; Marjanovic N; Miller CM; Mofsowitz S; Nair VD; Nunez E; Parent DM; Porter CK; Santa Ana E; Schilling M; Stadlbauer D; Sugiharto VA; Termini M; Sun P; Tracy RP; Krammer F; Bukreyev A; Ramos I; Sealfon SC
    Lancet Respir Med; 2021 Jul; 9(7):712-720. PubMed ID: 33865504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile.
    Iruretagoyena M; Vial MR; Spencer-Sandino M; Gaete P; Peters A; Delgado I; Perez I; Calderon C; Porte L; Legarraga P; Anderson A; Aguilera X; Vial P; Weitzel T; Munita JM
    BMC Infect Dis; 2021 May; 21(1):478. PubMed ID: 34039287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance study.
    Ladhani SN; Baawuah F; Beckmann J; Okike IO; Ahmad S; Garstang J; Brent AJ; Brent B; Walker J; Andrews N; Ireland G; Aiano F; Amin-Chowdhury Z; Letley L; Flood J; Jones SEI; Borrow R; Linley E; Zambon M; Poh J; Saliba V; Amirthalingam G; Lopez Bernal J; Brown KE; Ramsay ME
    Lancet Child Adolesc Health; 2021 Jun; 5(6):417-427. PubMed ID: 33740430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England.
    Ladhani SN; Ireland G; Baawuah F; Beckmann J; Okike IO; Ahmad S; Garstang J; Brent AJ; Brent B; Aiano F; Amin-Chowdhury Z; Kall M; Borrow R; Linley E; Zambon M; Poh J; Warrener L; Lackenby A; Ellis J; Amirthalingam G; Brown KE; Ramsay ME
    J Infect; 2021 Nov; 83(5):573-580. PubMed ID: 34400220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
    Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
    Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of seroprevalence in a cohort of university students of Rome (Italy) between September 2020 and July 2021.
    Ulivieri A; Morgante A; Magi F; Salehi LB; Lavra L
    Epidemiol Prev; 2022; 46(5-6):367-375. PubMed ID: 36628641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance-based informative testing for detection and containment of SARS-CoV-2 outbreaks on a public university campus: an observational and modelling study.
    Rennert L; McMahan C; Kalbaugh CA; Yang Y; Lumsden B; Dean D; Pekarek L; Colenda CC
    Lancet Child Adolesc Health; 2021 Jun; 5(6):428-436. PubMed ID: 33751952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. School mask policies and SARS-CoV-2 seroprevalence among school-age children-United States, September to December 2021.
    Nycz E; Deng Y; Van Dyke ME; Bratcher A; Shi J; Iachan R; Berney K; Jones JM; Clarke KEN
    Microbiol Spectr; 2024 Oct; 12(10):e0069124. PubMed ID: 39194255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study.
    Leidi A; Koegler F; Dumont R; Dubos R; Zaballa ME; Piumatti G; Coen M; Berner A; Darbellay Farhoumand P; Vetter P; Vuilleumier N; Kaiser L; Courvoisier D; Azman AS; Guessous I; Stringhini S;
    Clin Infect Dis; 2022 Mar; 74(4):622-629. PubMed ID: 34043763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
    Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
    Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay.
    McDade TW; McNally EM; Zelikovich AS; D'Aquila R; Mustanski B; Miller A; Vaught LA; Reiser NL; Bogdanovic E; Fallon KS; Demonbreun AR
    PLoS One; 2020; 15(8):e0237833. PubMed ID: 32797108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study.
    Gebrecherkos T; Kiros YK; Challa F; Abdella S; Gebreegzabher A; Leta D; Desta A; Hailu A; Tasew G; Abdulkader M; Tessema M; Tollera G; Kifle T; Arefaine ZG; Schallig HH; Adams ER; Urban BC; de Wit TFR; Wolday D
    PLoS One; 2022; 17(3):e0263627. PubMed ID: 35320286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
    Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.
    Gozlan Y; Reingold S; Koren R; Halpern O; Regev-Yochay G; Cohen C; Biber A; Picard O; Mendelson E; Lustig Y; Mor O
    Epidemiol Infect; 2021 Jun; 149():e153. PubMed ID: 34372950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
    Al-Mughales JA; Al-Mughales TJ; Saadah OI
    Front Immunol; 2021; 12():705441. PubMed ID: 34539635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.